Głębokie sekwencjonowanie kliniczne do diagnozowania patogennych wariantów mozaikowych w zaburzeniach rozwojowych kory mózgu i epilepsji
Clinical deep sequencing to diagnose pathogenic mosaic variants in malformations of cortical development and epilepsy
W skrócie
[Preprint - wstępne wyniki] Badacze z Boston Children's Hospital zbadali, czy głębokie sekwencjonowanie tkanki mózgu może pomóc w diagnozowaniu epilepsji i zaburzeń rozwojowych kory mózgu. Okazało się, że gdy badacze analizowali zmienioną tkankę, udało im się postawić diagnozę u 53% pacjentów (głównie znajdujące mutacje mozaikowe), a gdy badali zdrową tkankę, nie znaleźli żadnych istotnych zmian. Wszystkie odkryte genetyczne przyczyny były związane ze szlakiem mTOR, co otwiera możliwości nowych, spersonalizowanych terapii dla pacjentów z epilepsją.
Oryginalny abstract (angielski)
Background: and Objectives: Deep sequencing of brain tissue in the research setting has established that mosaic variants are a major cause of malformations of cortical development (MCDs) and epilepsy. However, genetic testing in the clinical setting primarily detects germline variants using clinically accessible samples. We aimed to determine the diagnostic yield and clinical utility of deep sequencing in the clinical setting to identify pathogenic mosaic variants for this population. Methods: We performed a retrospective cohort analysis of individuals at Boston Children's Hospital with MCDs with or without epilepsy who received clinical deep sequencing between September 2017 and February 2026. Demographic, clinical, and genetic testing data were abstracted from the medical record. For individuals without systemic features, we classified brain tissue as an affected tissue sample. For individuals with systemic features, we classified brain or relevant non-brain tissue as affected. The primary outcome was the diagnostic yield of clinical deep sequencing performed using affected vs unaffected tissue samples. The secondary outcome was the clinical utility of genetic diagnoses. Results: Our cohort included 37 individuals (19/37 (51%) female, 18/37 (49%) male) with MCDs, of whom 35/37 (95%) had epilepsy (25 with brain tissue samples available from epilepsy surgery) and 8/37 (22%) had systemic features. Most (35/37 (95%)) had dysplasia phenotypes on MRI and 12/27 (44%) with pathology available had Focal Cortical Dysplasia Type I or II. The diagnostic yield was 53% (17/32; 16 mosaic and 1 germline variant) when clinical deep sequencing was performed using an affected tissue sample vs 0% (0/6) using an unaffected tissue sample (p=0.016). Of the diagnosed cases, 13/17 (76%) had testing performed on brain tissue (1 with systemic features) and 4/17 (24%) on non-brain tissue (3 buccal and 1 duodenal tissue, all with systemic features). All but one diagnosis involved the mTOR pathway. All diagnoses had clinical utility. Discussion: Clinical deep sequencing, when performed using an affected tissue sample, has high diagnostic yield and clinical utility for individuals with MCDs, especially dysplasia phenotypes, and epilepsy. Our findings support implementation of clinical deep sequencing for this population, especially as the genetic diagnoses have implications for emerging precision therapies.